CLL Progression
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy (NCT04149821) | Weill Medical College of Cornell University | 2021-02-10 |
Track CLL Progression automatically
Every clearance here is in the API, with alerts when new ones post.